Tissue Regenix Group PLC
LSE:TRX

Watchlist Manager
Tissue Regenix Group PLC Logo
Tissue Regenix Group PLC
LSE:TRX
Watchlist
Price: 0.0725 GBX Market Closed
Market Cap: 5.2m GBX

TRX's latest stock split occurred on Apr 28, 2023

The company executed a 1-for-100 stock split, meaning that for every 100 shares held, investors received 1 new share.

Before the split, TRX traded at 0.605 per share. Afterward, the share price was about 60.

The adjusted shares began trading on Apr 28, 2023. This was TRX's 2nd stock split, following the previous one in Jun 29, 2010.

Last Splits:
Apr 28, 2023
1-for-100
Jun 29, 2010
1-for-5
Pre-Split Price
60.5 0.605
Post-Split Price
60
Before
After
Last Splits:
Apr 28, 2023
1-for-100
Jun 29, 2010
1-for-5

Tissue Regenix Group PLC
Stock Splits History

TRX Stock Splits Timeline
Apr 28, 2023
Apr 28, 2023
Split 1-for-100
/0.01
Pre-Split Price
60.5 0.605
Post-Split Price
60
Before
After
Jun 29, 2010
Jun 29, 2010
Split 1-for-5
/0.2
Pre-Split Price
1 000 2
Post-Split Price
875
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.13 0.13 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.41 8.41 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

Tissue Regenix Group PLC
Glance View

Market Cap
5.2m GBX
Industry
Biotechnology

Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. The company is headquartered in Leeds, West Yorkshire and currently employs 79 full-time employees. The company went IPO on 2006-12-21. The firm is focused on the development of regenerative products using its two platform technologies: decellularization (dCELL), which is used to produce allograft (DermaPure) and xenograft (OrthoPure XT) soft tissue products to promote healing and regeneration, and BioRinse, which is a natural bone filler solution verified to be osteoinductive to stimulate and regenerate native bone growth. The firm is engaged in transforming the treatment of patients in surgical applications, including BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology and Cardiac.

TRX Intrinsic Value
0.7743 GBX
Undervaluation 91%
Intrinsic Value
Price
Back to Top